Opinion
Volume 14:05, 2024

Journal of Nephrology & Therapeutics

ISSN: 2161-0959

Open Access

Understanding the Role of Metabolic Reprogramming in Kidney Cancer: From Bench to Bedside

Pierre Lefevre*

Department of Pediatric Gastroenterology, University of Paris, Paris, France

Introduction

Kidney cancer, particularly Renal Cell Carcinoma (RCC), is a leading cause of cancer-related mortality worldwide. Despite significant advances in surgical techniques and targeted therapies, the prognosis for advanced or metastatic RCC remains poor, highlighting the need for novel therapeutic approaches. Recent research has revealed that kidney cancer, like many other malignancies, is heavily influenced by metabolic reprogramming a process through which cancer cells alter their metabolic pathways to meet the increased demands for energy, biosynthesis, and survival in a hostile tumor microenvironment [1]. This shift from oxidative phosphorylation to aerobic glycolysis (often referred to as the Warburg effect) and other metabolic changes plays a crucial role in the initiation, progression, and metastasis of kidney cancer. Understanding the molecular underpinnings of these metabolic alterations opens new avenues for targeted therapies aimed at disrupting the unique metabolic characteristics of RCC cells. This article explores the role of metabolic reprogramming in kidney cancer and how these insights could translate from basic research ("bench") to clinical practice ("bedside") in the form of novel therapeutic strategies [2].

Description

Metabolic alterations in kidney cancer

In kidney cancer, metabolic reprogramming is a critical hallmark that supports the rapid proliferation and survival of tumor cells. One of the most prominent features of RCC is the dysregulation of the Hypoxia-Inducible Factor (HIF) pathway, particularly HIF-2α which is frequently overexpressed in Clear Cell RCC (ccRCC). This pathway drives changes in cellular metabolism by upregulating genes involved in glycolysis, glutaminolysis, and lipid metabolism, while simultaneously downregulating oxidative phosphorylation. These metabolic changes allow RCC cells to survive in low-oxygen (hypoxic) environments within the tumor. In addition to glycolysis, glutamine metabolism plays a crucial role in kidney cancer cells, as they rely on glutamine as a primary carbon source for nucleotide and amino acid synthesis. Furthermore, recent studies have highlighted the involvement of mitochondrial dysfunction in RCC, with altered mitochondrial dynamics contributing to the aggressive behavior of the tumor and its ability to metastasize. These metabolic adaptations are crucial for supporting the biosynthetic needs of rapidly dividing cancer cells and contribute to therapeutic resistance, making them important targets for new treatment strategies [3].

Targeting metabolic pathways in kidney cancer therapy

Given the central role of metabolic reprogramming in kidney cancer, targeting specific metabolic pathways offers a promising approach to therapy. One strategy involves inhibiting HIF-2α, which is responsible for activating the transcription of genes that drive the Warburg effect and other metabolic alterations. Several small molecule inhibitors targeting HIF-2αare currently in clinical trials, and early results show promise in inhibiting tumor growth and improving outcomes in patients with ccRCC. Another approach is targeting glutaminolysis, a critical pathway that supports the growth of RCC. Drugs like glutamine analogs and inhibitors of key enzymes in the glutamine metabolism pathway, such as glutaminase inhibitors, are being investigated as potential treatments. In addition to these, metabolic inhibitors targeting glycolysis (e.g., 3-bromopyruvate) and oxidative phosphorylation are also being explored as potential therapeutic agents. Another avenue of interest is the use of immune checkpoint inhibitors, as metabolic reprogramming in RCC cells can also influence the tumor microenvironment, leading to immune evasion. By combining metabolic therapies with immunotherapy, researchers hope to improve patient responses and overcome resistance to conventional treatments [4].

From bench to bedside: Clinical translation of metabolic targeting

The challenge in translating metabolic reprogramming therapies from the laboratory to the clinic lies in the complexity of metabolic networks and the heterogeneity of RCC. While preclinical models have shown promising results, translating these findings into effective clinical therapies requires overcoming significant obstacles, such as drug toxicity, patient variability, and the development of resistance. The use of biomarkers to identify patients who are most likely to benefit from metabolic therapies is a key step in making these approaches more personalized and effective. Recent advances in metabolomics the large-scale study of metabolites have provided insights into the metabolic profiles of RCC, helping to identify potential biomarkers for response to metabolic therapies. Additionally, combination therapies that target both metabolic pathways and immune checkpoints are gaining traction as a potential treatment strategy. Clinical trials are now underway to evaluate the safety and efficacy of several metabolic inhibitors, both as monotherapies and in combination with existing RCC therapies such as Tyrosine Kinase Inhibitors (TKIs) and immune checkpoint inhibitors [5].

Conclusion

Metabolic reprogramming is a hallmark of kidney cancer that supports tumor growth, survival, and metastasis. The dysregulation of metabolic pathways, such as glycolysis, glutaminolysis, and mitochondrial dysfunction, plays a central role in the pathogenesis of renal cell carcinoma. Understanding these metabolic alterations has opened new opportunities for developing targeted therapies aimed at disrupting the unique metabolic characteristics of RCC cells. While many promising therapeutic strategies are still in the preclinical or early clinical stages, recent advancements in drug development, including inhibitors of HIF-2α, glutaminolysis, and glycolysis, offer hope for more effective treatments. However, challenges such as patient heterogeneity, resistance mechanisms, and toxicity need to be addressed before these therapies can be widely used in clinical practice. As research continues to uncover the complexities of metabolic reprogramming in RCC, the integration of metabolic-targeted therapies with existing treatment regimens, including immunotherapy, could significantly improve the prognosis for patients with kidney cancer. Ultimately, metabolic reprogramming represents a promising frontier in kidney cancer research, with the potential to change the landscape of treatment and provide new hope for patients with this challenging malignancy.

***Address for Correspondence:** Pierre Lefevre, Department of Pediatric Gastroenterology, University of Paris, Paris, France, E-mail: pierre.lefevre@univ-paris.f*

Received: 02 September, 2024, Manuscript No. jnt-24-155679; **Editor Assigned:** 04 September, 2024, PreQC No. P-155679; **Reviewed:** 16 September, 2024, QC No. Q-155679; **Revised:** 23 September, 2024, Manuscript No. R-155679; **Published:** 30 September, 2024, DOI: 10.37421/2161-0959.2024.14.522

Acknowledgement

None.

Conflict of Interest

Authors declare no conflict of interest.

References

1. Shao, Yimin, Geheng Yuan, Junqing Zhang and Xiaohui Guo. "Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression." *Drug Des Devel Ther* (2015): 1177-1184.
2. Manning, Patrick, Pujika Emani Munasinghe, Jayanthi Bellae Papannarao and Andrew R. Gray, et al. "Acute weight loss restores dysregulated circulating microRNAs in individuals who are obese." *J Clin Endocrinol Metab* (2019): 1239-1248.
3. Dias, Sofia, Sílvia Paredes and Laura Ribeiro. "Drugs involved in dyslipidemia and obesity treatment: focus on adipose tissue." *Int J Endocrinol* (2018): 2637418.
4. Cherry, Paul, Cathal O'Hara, Pamela J. Magee and Emeir M. McSorley, et al. "Risks and benefits of consuming edible seaweeds." *Nutr Rev* (2019): 307-329.
5. Kamide, Kei. "CKD could be a new risk factor of dementia." *Hypertens Res* (2024): 1090-1091.

How to cite this article: Lefevre, Pierre. "Understanding the Role of Metabolic Reprogramming in Kidney Cancer: From Bench to Bedside." *J Nephrol Ther* 14 (2024): 522.